Systemic treatment in breast-cancer patients with brain metastasis

Bibliography

• Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985;35(2):219-26
   PubMed Web of Science ®Google Scholar
• Percy AK, Elveback LR, Okazaki H, Kurland LT. Neoplasms of the central nervous system. Epidemiologic considerations. Neurology 1972;22(1):40-8
   PubMed Web of Science ®Google Scholar
• Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22(17):3608-17
   PubMed Web of Science ®Google Scholar
• Tham YL, Sexton K, Kramer R, Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107(4):696-704
   PubMed Web of Science ®Google Scholar
• Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996;78(8):1781-8
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983;52(12):2349-54
   PubMed Web of Science ®Google Scholar
• DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast-cancer patients with brain metastases. Cancer 1979;44(5):1913-8
   PubMed Web of Science ®Google Scholar
• Issa CM, Semrau R, Kath R, Hoffken K. Isolated brain metastases as the sole manifestation of a late relapse in breast cancer. J Cancer Res Clin Oncol 2002;128(1):61-3
   PubMed Web of Science ®Google Scholar
• Lagerwaard FJ, Levendag PC, Nowak PJ, Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43(4):795-803
   PubMed Web of Science ®Google Scholar
• Weil RJ, Palmieri DC, Bronder JL, Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167(4):913-20
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33(1):49-54
   PubMed Web of Science ®Google Scholar
• Altundag K, Bondy ML, Mirza NQ, Clinicopathologic characteristics and prognostic factors in 420 metastatic breast-cancer patients with central nervous system metastasis. Cancer 2007;110(12):2640-7
   PubMed Web of Science ®Google Scholar
• Xenidis N, Perraki M, Kafousi M, Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast-cancer patients. J Clin Oncol 2006;24(23):3756-62
   PubMed Web of Science ®Google Scholar
• Souglakos J, Vamvakas L, Apostolaki S, Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res 2006;8(4):R36
   Web of Science ®Google Scholar
• Boogerd W, Vos VW, Hart AA, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 1993;15(2):165-74
   PubMed Web of Science ®Google Scholar
• Lee SS, Ahn JH, Kim MK, Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 2008;111(3):523-30
   PubMed Web of Science ®Google Scholar
• Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69(4):972-80
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M, Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37(4):745-51
   PubMed Web of Science ®Google Scholar
• Evans AJ, James JJ, Cornford EJ, Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004;16(5):345-9
   PubMed Web of Science ®Google Scholar
• Hicks DG, Short SM, Prescott NL, Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30(9):1097-104
   PubMed Web of Science ®Google Scholar
• Miller KD, Weathers T, Haney LG, Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003;14(7):1072-7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 2004;101(8):1760-6
   PubMed Web of Science ®Google Scholar
• Ryberg M, Nielsen D, Osterlind K, Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 2005;91(3):217-25
   PubMed Web of Science ®Google Scholar
• Gabos Z, Sinha R, Hanson J, Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24(36):5658-63
   PubMed Web of Science ®Google Scholar
• Clayton AJ, Danson S, Jolly S, Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91(4):639-43
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Kahlert S, Siekiera W, Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006;15(2):219-25
   PubMed Web of Science ®Google Scholar
• Bendell JC, Domchek SM, Burstein HJ, Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97(12):2972-7
   PubMed Web of Science ®Google Scholar
• Yau T, Swanton C, Chua S, Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006;45(2):196-201
   PubMed Web of Science ®Google Scholar
• Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004;40(3):379-82
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112(3):533-43
   PubMed Web of Science ®Google Scholar
• Lin NU, Dieras V, Paul D, EGF 105084 Study Group. EGF105084, a phase II study of lapatinib for brain metastases in patients with HER2+ breast cancer following trastuzumab based systemic therapy and cranial radiotherapy. 2007 ASCO Annual Meeting Abstract No: 1012
   Google Scholar
• Harputluoglu H, Dizdar O, Aksoy S, Characteristics of breast-cancer patients with central nervous system metastases: a single-center experience. J Natl Med Assoc 2008;100(5):521-6
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Soussain C, Jahnke K, Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007;25(16):2295-305
   PubMed Web of Science ®Google Scholar
• Palmieri D, Smith QR, Lockman PR, Brain metastases of breast cancer. Breast Dis 2006;26:139-47
   PubMedGoogle Scholar
• Wang ML, Yung WK, Royce ME, Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 2001;24(4):421-4
   PubMed Web of Science ®Google Scholar
• Zulkowski K, Kath R, Semrau R, Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 2002;128(2):111-3
   PubMed Web of Science ®Google Scholar
• Kurt M, Aksoy S, Hayran M, Guler N. A retrospective review of breast-cancer patients with central nervous system metastasis treated with capecitabine. 2007 ASCO Annual Meeting Abstract No: 1098
   Google Scholar
• Boogerd W, Tjahja IS, van de Sandt MM, Beijnen JH. Penetration of idarubicin into malignant brain tumor tissue. J Neurooncol 1999;44(1):65-9
   PubMed Web of Science ®Google Scholar
• Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995;76(2):232-6
   PubMed Web of Science ®Google Scholar
• Crivellari D, Pagani O, Veronesi A, High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001;12(3):353-6
   PubMed Web of Science ®Google Scholar
• Schwonzen M, Kurbacher CM, Mallmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000;11(9):681-5
   PubMed Web of Science ®Google Scholar
• Wilson WH, Berg SL, Bryant G, Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12(8):1621-9
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Francis P, Quinaux E, Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol 2008;19(11):1837-41
   PubMed Web of Science ®Google Scholar
• Labidi SI, Bachelot T, Ray-Coquard I, Bevacizumab and paclitaxel for breast-cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 2009;9(2):118-21
   PubMed Web of Science ®Google Scholar
• Baker SD, Heideman RL, Crom WR, Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996;37(3):195-202
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Luftner DI, Egorin MJ, The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Ann Oncol 2001;12(1):119-22
   PubMed Web of Science ®Google Scholar
• Oberhoff C, Kieback DG, Wurstlein R, Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001;24(3):256-60
   PubMedGoogle Scholar
• Gruschow K, Klautke G, Fietkau R. Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. Eur J Cancer 2002;38(3):367-74
   PubMed Web of Science ®Google Scholar
• Kocher M, Eich HT, Semrau R, Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther Onkol 2005;181(1):20-5
   PubMed Web of Science ®Google Scholar
• Hedde JP, Neuhaus T, Schuller H, A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors. Int J Radiat Oncol Biol Phys 2007;68(3):839-44
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Mikhael NZ, Nair RC, Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 1988;11(2):152-8
   PubMed Web of Science ®Google Scholar
• Cocconi G, Lottici R, Bisagni G, Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;8(3-4):327-34
   PubMed Web of Science ®Google Scholar
• Franciosi V, Cocconi G, Michiara M, Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85(7):1599-605
   PubMed Web of Science ®Google Scholar
• Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001;2(9):552-60
   PubMed Web of Science ®Google Scholar
• Abrey LE, Olson JD, Raizer JJ, A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53(3):259-65
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Kosmidis P, Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12(2):249-54
   PubMed Web of Science ®Google Scholar
• Preuss I, Eberhagen I, Haas S, O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer 1995;61(3):321-6
   PubMed Web of Science ®Google Scholar
• Tosoni A, Franceschi E, Ermani M, Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 2008;89(2):179-85
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Cavallo G, Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006;95(9):1155-60
   PubMed Web of Science ®Google Scholar
• Trudeau ME, Crump M, Charpentier D, Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada–Clinical Trials Group (NCIC-CTG). Ann Oncol 2006;17(6):952-6
   PubMed Web of Science ®Google Scholar
• Friedman HS. Phase II trial of temozolomide for patients with progressive brain metastases. 2003 ASCO Annual Meeting (Central Nervous System Session, Poster Discussion)
   Google Scholar
• Addeo R, De Rosa C, Faiola V, Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast-cancer patients with brain metastases. Cancer 2008;113(9):2524-31
   PubMed Web of Science ®Google Scholar
• Kouvaris JR, Miliadou A, Kouloulias VE, Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 2007;30(7):361-6
   PubMed Web of Science ®Google Scholar
• Antonadou D, Paraskevaidis M, Sarris G, Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20(17):3644-50
   PubMed Web of Science ®Google Scholar
• Verger E, Gil M, Yaya R, Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005;61(1):185-91
   PubMed Web of Science ®Google Scholar
• Rivera E, Meyers C, Groves M, Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006;107(6):1348-54
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Linardou H, Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005;71(1):61-5
   PubMed Web of Science ®Google Scholar
• Melisko ME, Anderson M, Scott J, Phase II study of irinotecan and temozolomide in breast-cancer patients with brain metastases or leptomeningeal disease that has progressed after stereotactic radiosurgery or whole brain radiation. 2009 ASCO Breast cancer Symposium, Abstract No: 237
   Google Scholar
• Caraglia M, Addeo R, Costanzo R, Pegylated liposomal doxorubicin plus temozolamide in the salvage treatment of brain metastases: The update. 2004 ASCO Annual Meeting, Abstract No: 1576
   Google Scholar
• Iwamoto FM, Omuro AM, Raizer JJ, A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2008;87(1):85-90
   PubMed Web of Science ®Google Scholar
• Omuro AM, Raizer JJ, Demopoulos A, Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol 2006;78(3):277-80
   PubMed Web of Science ®Google Scholar
• Ekenel M, Hormigo AM, Peak S, Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007;85(2):223-7
   PubMed Web of Science ®Google Scholar
• Naskhletashvili DR, Gorbounova VA, Bychkov MB, Capecitabine monotherapy for patients with brain metastases from advanced breast cancer. 2009 ASCO Annual Meeting, Abstract No: 1102
   Google Scholar
• Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58(4):832-9
   PubMed Web of Science ®Google Scholar
• Donadio M, Ardine M, Berruti A, Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 2003;52(2):147-52
   PubMed Web of Science ®Google Scholar
• Murphy C, Nulsen B, Rump M, Phase II trial of patupilone in patients with breast cancer metastases progressing or recurring after whole brain radiotherapy. 2009 ASCO Breast Cancer Symposium, Abstract No: 234
   Google Scholar
• Conlin AK, D'andrea G, Hudis CA, Phase II trial of patupilone in patients with breast cancer brain metastases progressing or recurring after whole brain radiotherapy. 2008 ASCO Annual Meeting, Abstract No: 1086
   Google Scholar
• Glantz MJ, Cole BF, Recht L, High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998;16(4):1561-7
   PubMed Web of Science ®Google Scholar
• Lassman AB, Abrey LE, Shah GD, Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006;78(3):255-60
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Neoplastic meningitis. Neurologist 2006;12(4):179-87
   PubMed Web of Science ®Google Scholar
• Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis–the role of multimodality treatment. J Neurooncol 2007;84(1):57-62
   PubMed Web of Science ®Google Scholar
• Boogerd W, van den Bent MJ, Koehler PJ, The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004;40(18):2726-33
   PubMed Web of Science ®Google Scholar
• Grossman SA, Finkelstein DM, Ruckdeschel JC, Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993;11(3):561-9
   PubMed Web of Science ®Google Scholar
• Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5(10):1655-62
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Yamada M, Maeda N, Clinical trial of intrathecal administration of 5-fluoro-2'-deoxyuridine for treatment of meningeal dissemination of malignant tumors. J Neurooncol 1999;45(2):175-83
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27(31):5278-86
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Schmitt M, Willems A, Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast-cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18(1):23-8
   PubMed Web of Science ®Google Scholar
• Park YH, Park MJ, Ji SH, Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast-cancer patients. Br J Cancer 2009;100(6):894-900
   PubMed Web of Science ®Google Scholar
• Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006;7(9):778-80
   PubMed Web of Science ®Google Scholar
• Mir O, Ropert S, Alexandre J, High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 2008;19(11):1978-80
   PubMed Web of Science ®Google Scholar
• Gril B, Palmieri D, Bronder JL, Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100(15):1092-103
   PubMedGoogle Scholar
• Lin NU, Carey LA, Liu MC, Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26(12):1993-9
   PubMed Web of Science ®Google Scholar
• Lin NU, Dieras V, Paul D, Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15(4):1452-9
   PubMed Web of Science ®Google Scholar
• Socinski MA, Langer CJ, Huang JE, Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27(31):5255-61
   PubMed Web of Science ®Google Scholar
• Palmieri D, Lockman PR, Thomas FC, Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009;15(19):6148-57
   PubMed Web of Science ®Google Scholar
• Baschnagel A, Russo A, Burgan WE, Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009;8(6):1589-95
   PubMed Web of Science ®Google Scholar